According to the latest data published by the CodeBreak 100 study (5), among the 59 patients who carry the KRAS G12C mutation in patients with advanced NSCLC undergoing multi-line therapy, a total of 19 patients had definite objective remission, with an ORR of 32.2% [95% CI: 20.62–45.64]; 52 patients had clear disease controVS-6766l, with a DCR of 88.1% (95% CI: 77.07–95.09). This evidence concerns the gene KRAS and non-small cell lung carcinoma.